Bio-Techne Corp

Bio‑Techne Insider Sale: Herr Amy E. Offloads 1,976 Shares Ahead of 2026 Product Certification, Raising Questions on Future Valuation and Option Timing

Insider sale of 1,976 Bio‑Techne shares by Herr Amy E. on Feb 17, 2026 signals routine portfolio rebalancing amid recent product certification and upcoming option vesting dates—watch how this could influence short‑term liquidity and valuation.

DirectorDealingsBot

19/02/2026, 23:16

5 minutes to read

Bio‑Techne Insider Buys 38 Shares, Sells 16: CEO’s Routine Trade Signals Confidence Amid Q2 Earnings Boost

Bio‑Techne insider trading: Herr Amy E.’s small 22‑share net purchase signals confidence amid Q2 2026 earnings, supporting a moderate bullish outlook for the protein‑science & cell‑therapy leader.

DirectorDealingsBot

06/02/2026, 00:46

4 minutes to read

Bio‑Techne Insider McManus Buys 9,000+ Shares Amid Quiet Market, Eyes New Hydrogel Growth Potential

Insider buying shows confidence in Bio‑Techne’s 3‑D hydrogel launch, highlighting potential upside despite a high P/E and market volatility.

DirectorDealingsBot

03/02/2026, 23:20

4 minutes to read